Sherrington Robin - Mar 4, 2022 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Signature
/s/ Cassandra Robinson, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Mar 4, 2022
Transactions value $
-$656,896
Form type
4
Date filed
3/8/2022, 06:35 PM
Previous filing
Jun 1, 2021
Next filing
Mar 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $4.53K +1.23K +3.83% $3.67* 33.5K Mar 4, 2022 Direct F1
transaction XENE Common Shares Tax liability -$21.9K -696 -2.08% $31.42 32.8K Mar 4, 2022 Direct F2
transaction XENE Common Shares Options Exercise $22.7K +6.17K +18.83% $3.67* 38.9K Mar 4, 2022 Direct F1
transaction XENE Common Shares Sale -$205K -6.71K -17.23% $30.56 32.2K Mar 4, 2022 Direct F2
transaction XENE Common Shares Sale -$151K -5K -15.51% $30.15 27.2K Mar 4, 2022 Direct F3
transaction XENE Common Shares Sale -$155K -5K -18.36% $31.05 22.2K Mar 4, 2022 Direct F4
transaction XENE Common Shares Sale -$151K -5K -22.49% $30.23 17.2K Mar 4, 2022 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -1.23K -100% $0.00* 0 Mar 4, 2022 Common Shares 1.23K $3.67 Direct F1, F6, F7
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -6.17K -100% $0.00* 0 Mar 4, 2022 Common Shares 6.17K $3.67 Direct F1, F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
F2 Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
F3 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.10 to $31.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.78 to $31.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.15 to $30.33, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6 1/3 of the shares subject to the Option vested on January 1, 2012 (the "First 2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the First 2012 Vesting Commencement Date over the following 4 years.
F7 Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period.
F8 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "Second 2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the Second 2012 Vesting Commencement Date